Aktienanalyse wird geladen …
RMD · NYSE · Medical Devices · USA
221,88 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5,65 Mrd. | 1,52 Mrd. | 10,43 $ | 146,05 Mio. | 0,5 Mio · 0,3 % | 1,8 Mio · 1,2 % | 61,1 % | 26,9 % | 11,29 $ | 0,71 $ | 2,40 $ |
| 2025 | 5,15 Mrd. | 1,4 Mrd. | 9,51 $ | 147,34 Mio. | 0,4 Mio · 0,3 % | 0,6 Mio · 0,4 % | 59,4 % | 27,2 % | 11,28 $ | 0,62 $ | 2,12 $ |
| 2024 | 4,69 Mrd. | 1,02 Mrd. | 6,92 $ | 147,55 Mio. | 0,4 Mio · 0,2 % | 0,3 Mio · 0,2 % | 56,7 % | 21,8 % | 8,82 $ | 0,54 $ | 1,92 $ |
| 2023 | 4,22 Mrd. | 897,56 Mio. | 6,09 $ | 147,46 Mio. | 0,3 Mio · 0,2 % | — | 55,8 % | 21,3 % | 3,89 $ | 0,48 $ | 1,76 $ |
| 2022 | 3,58 Mrd. | 779,44 Mio. | 5,30 $ | 147,04 Mio. | 0,3 Mio · 0,2 % | — | 56,6 % | 21,8 % | 1,47 $ | 0,44 $ | 1,68 $ |
| 2021 | 3,2 Mrd. | 474,51 Mio. | 3,24 $ | 146,45 Mio. | 0,3 Mio · 0,2 % | — | 57,5 % | 14,8 % | 4,33 $ | 0,44 $ | 1,56 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,46 Mrd. | 383,43 Mio. | 2,63 $ | — | 58,8 % | 26,2 % | 2,76 $ |
| Q1 2026 | 1,43 Mrd. | 398,73 Mio. | 2,74 $ | 145,72 Mio. | 62,3 % | 27,9 % | 3,57 $ |
| Q4 2025 | 1,42 Mrd. | 392,59 Mio. | 2,68 $ | 146,37 Mio. | 61,8 % | 27,6 % | 2,13 $ |
| Q3 2025 | 1,34 Mrd. | 348,54 Mio. | 2,37 $ | 146,9 Mio. | 61,5 % | 26,1 % | 2,82 $ |
| Q2 2025 | 1,35 Mrd. | 379,71 Mio. | 2,60 $ | 147,04 Mio. | 60,8 % | 28,2 % | 3,48 $ |
| Q1 2025 | 1,29 Mrd. | 365,04 Mio. | 2,48 $ | 147,22 Mio. | 59,3 % | 28,3 % | 3,79 $ |
| Q4 2024 | 1,28 Mrd. | 344,62 Mio. | 2,34 $ | 147,48 Mio. | 58,6 % | 26,9 % | 1,95 $ |
| Q3 2024 | 1,22 Mrd. | 311,36 Mio. | 2,11 $ | 147,6 Mio. | 58,6 % | 25,4 % | 2,08 $ |
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
This Analyst Just Upgraded ResMed Stock. Here's Why.
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care. ResMed develops and markets cloud-connected medical devices, including positive airway pressure systems, masks, home ventilators, and related accessories used to diagnose and manage sleep apnea and other chronic respiratory disorders. The company also provides software and connected-care platforms that support home healthcare, post-acute care, and care coordination for providers, patients, and caregivers. Its product portfolio serves hospitals, sleep clinics, home medical equipment suppliers, and long-term care organizations across global markets. ResMed Inc. plays an important role in the healthcare market by combining medical devices with software to improve treatment delivery, patient monitoring, and care management in home and clinical settings.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest RMD und jede andere Aktie unbegrenzt.